• Je něco špatně v tomto záznamu ?

Genetic variation in the ADIPOQ gene and serum adiponectin increase the risk of bladder cancer

L. Elsalem, MA. Alfaqih, S. Al Bashir, O. Halalsheh, HA. Basheer, K. Mhedat, Y. Khader, K. Pors

. 2022 ; 20 (3) : 106-113. [pub] 20220803

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22026976

Grantová podpora
20200263 Deanship of Research of Jordan University of Science and Technology

Bladder cancer (BC) is the 10th most common cancer worldwide. Genetic studies estimated 30% heritability in BC risk. Adiponectin is an adipocytokine that has important roles in the regulation of energy metabolism. Recent evidence suggests dysregulation of adiponectin levels in BC tissues. Serum level of adiponectin is influenced by single nucleotide polymorphisms (SNPs) in the ADIPOQ gene. However, limited evidence is available regarding the association between adiponectin serum levels or SNPs in ADIPOQ and BC risk. This study aimed to assess whether adiponectin serum levels or SNPs in ADIPOQ may modify BC risk. In this case-control study, 114 BC patients were recruited along with 114 controls. Study subjects were genotyped for variations in ADIPOQ SNPs, namely rs17300539, rs266729, rs2241766, and rs1501299. Adiponectin levels were measured from the serum of study subjects. Our analysis showed that the G allele and the GG genotype of rs1501299 were significantly more frequent in BC patients compared to those in the control group (p-value < 0.05). Moreover, two ADIPOQ haplotypes containing the above G allele were associated with increased BC risk (p-value < 0.05). Multivariate analysis showed that increased serum adiponectin, smoking or age were all significant predictors of BC (p-value < 0.05). The data supports use of serum adiponectin and the G allele of rs1501299 SNP in ADIPOQ as potential biomarkers and/or targets in BC. To further validate findings in this study, larger populations of various ethnicities and/or genetic backgrounds are required. More investigations on the functional role of adiponectin in BC will also provide better understanding of potential targeting adiponectin for BC treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22026976
003      
CZ-PrNML
005      
20230210111625.0
007      
ta
008      
221108s2022 xr f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2022.012 $2 doi
035    __
$a (PubMed)36218131
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Elsalem, Lina $u Jordan University of Science and Technology, Faculty of Medicine, Department of Pharmacology, Irbid, Jordan
245    10
$a Genetic variation in the ADIPOQ gene and serum adiponectin increase the risk of bladder cancer / $c L. Elsalem, MA. Alfaqih, S. Al Bashir, O. Halalsheh, HA. Basheer, K. Mhedat, Y. Khader, K. Pors
520    9_
$a Bladder cancer (BC) is the 10th most common cancer worldwide. Genetic studies estimated 30% heritability in BC risk. Adiponectin is an adipocytokine that has important roles in the regulation of energy metabolism. Recent evidence suggests dysregulation of adiponectin levels in BC tissues. Serum level of adiponectin is influenced by single nucleotide polymorphisms (SNPs) in the ADIPOQ gene. However, limited evidence is available regarding the association between adiponectin serum levels or SNPs in ADIPOQ and BC risk. This study aimed to assess whether adiponectin serum levels or SNPs in ADIPOQ may modify BC risk. In this case-control study, 114 BC patients were recruited along with 114 controls. Study subjects were genotyped for variations in ADIPOQ SNPs, namely rs17300539, rs266729, rs2241766, and rs1501299. Adiponectin levels were measured from the serum of study subjects. Our analysis showed that the G allele and the GG genotype of rs1501299 were significantly more frequent in BC patients compared to those in the control group (p-value < 0.05). Moreover, two ADIPOQ haplotypes containing the above G allele were associated with increased BC risk (p-value < 0.05). Multivariate analysis showed that increased serum adiponectin, smoking or age were all significant predictors of BC (p-value < 0.05). The data supports use of serum adiponectin and the G allele of rs1501299 SNP in ADIPOQ as potential biomarkers and/or targets in BC. To further validate findings in this study, larger populations of various ethnicities and/or genetic backgrounds are required. More investigations on the functional role of adiponectin in BC will also provide better understanding of potential targeting adiponectin for BC treatment.
650    12
$a adiponektin $x krev $x genetika $7 D052242
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a jednonukleotidový polymorfismus $7 D020641
650    12
$a nádory močového měchýře $x genetika $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Alfaqih, Mahmoud A $u Jordan University of Science and Technology, Faculty of Medicine, Department of Physiology and Biochemistry, Irbid, Jordan
700    1_
$a Al Bashir, Samir $u Jordan University of Science and Technology, Faculty of Medicine, Department of Pathology and Microbiology, Irbid, Jordan
700    1_
$a Halalsheh, Omar $u Jordan University of Science and Technology, Faculty of Medicine, Department of General Surgery and Urology, Irbid, Jordan
700    1_
$a Basheer, Haneen A $u Zarqa University, Faculty of Pharmacy, Zarqa, Jordan
700    1_
$a Mhedat, Khawla $u Jordan University of Science and Technology, Faculty of Medicine, Department of Physiology and Biochemistry, Irbid, Jordan
700    1_
$a Khader, Yousef $u Jordan University of Science and Technology, Faculty of Medicine, Department of Public Health and Community Medicine, Irbid, Jordan
700    1_
$a Pors, Klaus $u University of Bradford, Faculty of Life Sciences, The School of Pharmacy and Medical Sciences, Institute of Cancer Therapeutics, West Yorkshire, United Kingdom
773    0_
$w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 20, č. 3 (2022), s. 106-113
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36218131 $y Pubmed
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20221108 $b ABA008
991    __
$a 20230210111616 $b ABA008
999    __
$a ok $b bmc $g 1896148 $s 1178283
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 20 $c 3 $d 106-113 $e 20220803 $i 1214-0287 $m Journal of Applied Biomedicine $n J. Appl. Biomed. (Čes. Budějovice Print) $x MED00012667
GRA    __
$a 20200263 $p Deanship of Research of Jordan University of Science and Technology
LZP    __
$b NLK138 $a Pubmed-20221108

Najít záznam

Citační ukazatele

Možnosti archivace